AMRX

Company Overview — What Does Amneal Pharmaceuticals, Inc. Do?

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals, Inc. (AMRX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chintu Patel and employs approximately 7,600 people. With a market capitalization of $4.1B, AMRX is one of the notable companies in the Healthcare sector.

Amneal Pharmaceuticals, Inc. (AMRX) Stock Rating — Hold (April 2026)

As of April 2026, Amneal Pharmaceuticals, Inc. receives a Hold rating with a composite score of 50.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AMRX ranks #1,970 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Amneal Pharmaceuticals, Inc. ranks #208 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AMRX Stock Price and 52-Week Range

Amneal Pharmaceuticals, Inc. (AMRX) currently trades at $12.54. The stock lost $0.26 (2.0%) in the most recent trading session. The 52-week high for AMRX is $15.42, which means the stock is currently trading -18.7% from its annual peak. The 52-week low is $6.68, putting the stock 87.6% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.

Is AMRX Overvalued or Undervalued? — Valuation Analysis

Amneal Pharmaceuticals, Inc. (AMRX) carries a value factor score of 61/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 43.61x, compared to the Healthcare sector average of 23.63x — a premium of 85%. The price-to-sales ratio is 1.35x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AMRX trades at 17.53x EV/EBITDA, versus 6.34x for the sector.

Overall, AMRX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Amneal Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Amneal Pharmaceuticals, Inc. (AMRX) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at 2.5% versus the sector average of -33.1%.

On a margin basis, Amneal Pharmaceuticals, Inc. reports gross margins of 37.4%, compared to 71.5% for the sector. The operating margin is 12.9% (sector: -66.1%). Net profit margin stands at 3.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 11.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AMRX Debt, Balance Sheet, and Financial Health

Balance sheet data for AMRX is evaluated through our stability factor. The current ratio is 2.17x, indicating strong short-term liquidity. Total debt on the balance sheet is $2.57B. Cash and equivalents stand at $201M.

AMRX has a beta of 0.87, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Amneal Pharmaceuticals, Inc. is 70/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

Amneal Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Amneal Pharmaceuticals, Inc. reported revenue of $2.91B and earnings per share (EPS) of $0.23. Net income for the quarter was $90M. Gross margin was 37.4%. Operating income came in at $371M.

In FY 2025, Amneal Pharmaceuticals, Inc. reported revenue of $3.02B and earnings per share (EPS) of $0.23. Net income for the quarter was $128M. Gross margin was 36.9%. Revenue grew 8.0% year-over-year compared to FY 2024. Operating income came in at $394M.

In Q3 2025, Amneal Pharmaceuticals, Inc. reported revenue of $785M and earnings per share (EPS) of $0.01. Net income for the quarter was $18M. Gross margin was 34.9%. Revenue grew 11.7% year-over-year compared to Q3 2024. Operating income came in at $70M.

In Q2 2025, Amneal Pharmaceuticals, Inc. reported revenue of $725M and earnings per share (EPS) of $0.07. Net income for the quarter was $36M. Gross margin was 39.5%. Revenue grew 3.2% year-over-year compared to Q2 2024. Operating income came in at $111M.

Over the past 8 quarters, Amneal Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $702M to $2.91B. Investors analyzing AMRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AMRX Dividend Yield and Income Analysis

Amneal Pharmaceuticals, Inc. (AMRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AMRX Momentum and Technical Analysis Profile

Amneal Pharmaceuticals, Inc. (AMRX) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AMRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Amneal Pharmaceuticals, Inc. (AMRX) ranks #208 out of 838 stocks based on the Blank Capital composite score. This places AMRX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AMRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AMRX vs S&P 500 (SPY) comparison to assess how Amneal Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

AMRX Next Earnings Date

No upcoming earnings date has been announced for Amneal Pharmaceuticals, Inc. (AMRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AMRX? — Investment Thesis Summary

Amneal Pharmaceuticals, Inc. presents a balanced picture with arguments on both sides. The value score of 61/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 61/100, suggesting the trend favors buyers. Low volatility (stability score 70/100) reduces downside risk.

In summary, Amneal Pharmaceuticals, Inc. (AMRX) earns a Hold rating with a composite score of 50.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AMRX stock.

Related Resources for AMRX Investors

Explore more research and tools: AMRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AMRX head-to-head with peers: AMRX vs AZN, AMRX vs SLGL, AMRX vs VMD.